

**INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
FENG QIN, M.D. AND QIN MEDICAL PC**

I. PREAMBLE

Feng Qin, M.D. and Qin Medical PC (Collectively, Qin) hereby enters into this Integrity Agreement (IA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, program requirements, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). This IA applies to Qin, any entity that provides items or services that will be billed to Federal health care programs in which Qin has an ownership or control interest, as defined in 42 U.S.C. § 1320a-3(a)(3), at any time during the term of the IA, and to any other Covered Persons of Qin as defined in Section II.C. Contemporaneously with this IA, Qin is entering into a Settlement Agreement with the United States.

II. TERM AND SCOPE OF THE IA

A. This IA shall have a term of three years from the Effective Date. The Effective Date shall be the date on which the final signatory signs this IA. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

B. Sections VII, X, and XI shall expire no later than 120 days from OIG’s receipt of: (1) Qin’s final Annual Report; or (2) any additional materials submitted by Qin pursuant to OIG’s request, whichever is later.

C. The term “Covered Persons” includes:

1. Qin and all employees of Qin;

2. all contractors, agents, and other persons who provide patient care items or services or who perform billing or coding functions on behalf of Qin; and

3. all employees of any entity that provides items or services that will be billed to Federal health care programs in which Qin has an ownership or control interest (as defined in 42 U.S.C. §1320a-3(a)(3)) at any time during the term of this I.A.

III. INTEGRITY OBLIGATIONS

Qin shall establish and maintain a Compliance Program that includes the following elements:

A. Posting of Notice

Within 60 days after the Effective Date, Qin shall post in a prominent place accessible to all patients and Covered Persons a notice that provides the HHS OIG Fraud Hotline telephone number (1-800-HHS-TIPS) as a confidential means by which suspected fraud or abuse in the Federal health care programs may be reported.

B. Training and Education

1. *Training.* Qin and all other Covered Persons shall receive at least three hours of training during the first Reporting Period, including at least one hour of training to be completed within 60 days after the Effective Date. Training may be completed in-person or on-line. These training requirements may be satisfied only by the completion of courses provided by the Centers for Medicare & Medicaid Services (CMS) Medicare Learning Network (MLN), Qin's Medicare contractor, or other training courses that are submitted to OIG, prior to registration for the training course, for review and approval.

At a minimum, the required training sessions must include the following topics:

- a. the Federal health care program billing, coding and claim submission statutes, regulations, and program requirements and directives relating to the items or services furnished by Qin; and
- b. the Federal health care program medical record documentation requirements relating to items or services furnished by Qin.

New Covered Persons shall receive at least three hours of training within 45 days after becoming a Covered Person. A new Covered Person shall work under the direct supervision of a Covered Person who has received such training, to the extent that the work relates to the delivery of patient care items or services and/or the preparation or submission of claims for reimbursement from any Federal health care program, until such time as the new Covered Person completes the training.

The OIG may, in its discretion, require that Qin and other Covered Persons complete additional hours of training regarding the topics identified above, or additional topics, in the second and third years of the IA. The OIG shall provide notice to Qin of such additional required training at least 180 days prior to the required completion date for such training.

2. *Certification.* Qin shall maintain written documentation (e.g., written or electronic certificates of completion from the training provider) that all Covered Persons required to receive training have in fact completed such training. The documentation shall specify the type of training received and the date received.

C. Review Procedures

1. *General Description.*

- a. *Engagement of Independent Review Organization.* Within 60 days after the Effective Date, Qin shall engage one or more individuals or entities, such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.C. The IRO(s) must have the qualifications and must be able to meet the other requirements relating to the IRO outlined in Appendix A to this IA, which is incorporated by reference.
- b. *Retention of Records.* The IRO(s) and Qin shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Qin) related to the reviews.

2. *Claims Review.* The IRO shall conduct a review of Qin's coding, billing, and claims submission to the Federal health care programs and the reimbursement received for services and procedures performed by Qin, for each three-month period during the term of this IA (Quarterly Claims Review) and shall prepare a Quarterly Claims Review Report, as outlined in Appendix B to this IA, which is incorporated by reference. The first three-month period for purposes of the Quarterly Claims Review requirement shall begin 30 days after the Effective Date. Each Quarterly Claims Review Report shall be submitted to OIG within 60 days following the end of the three-month period covered by the Quarterly Claims Review.

3. *Dialysis Access Procedures Review.* The IRO shall evaluate and analyze the medical necessity and appropriateness of AV dialysis access interventions and dialysis access dysfunction diagnostic tests performed or ordered by Qin for each Reporting Period during the term of this IA (Dialysis Access Procedures Review). In conducting the Dialysis Access Procedures Review, the IRO shall review the AV dialysis access interventions and dialysis access dysfunction diagnostic tests for appropriateness of case selection, quality of procedure or test, execution, proper response to intraprocedural problems, accurate assessment of procedure or test outcome, and appropriateness of procedure or test management. The procedures shall be reviewed based on the supporting documentation available from Qin or under Qin's control and applicable regulations and guidance, including but not limited to the established practice guidelines and generally accepted standards practice described by the Local Coverage Determination for Dialysis Access Maintenance to determine whether the procedure was medically necessary and appropriate. The IRO shall prepare a Dialysis Access Procedures Review Report, as outlined in Appendix B to this IA, which is incorporated by reference. .

4. *Validation Review.* In the event OIG has reason to believe that: (a) any Quarterly Claims Review or Dialysis Access Procedures Review fails to conform to the requirements of this IA; or (b) the IRO's findings, Quarterly Claims Review, or Dialysis Access Procedures Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Quarterly Claims Review or Dialysis Access Procedures Review complied with the requirements of the IA and/or the findings or Quarterly Claims Review or Dialysis Access Procedures Review results are inaccurate (Validation Review). Qin shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents so long as it is initiated within one year after Qin's final submission (as described in Section II) is received by OIG.

Prior to initiating a Validation Review, OIG shall notify Qin in writing of its intent to conduct a Validation Review and the reasons OIG has determined a Validation Review

is necessary. Qin shall have up to 30 days following the date of the OIG's written notice to submit a written response to OIG that includes any additional or relevant information to clarify the results of the Quarterly Claims Review or Dialysis Access Procedures Review or to correct the inaccuracy of the Quarterly Claims Review or Dialysis Access Procedures Review and/or to propose alternatives to the proposed Validation Review. OIG will attempt in good faith to resolve any Quarterly Claims Review or Dialysis Access Procedures Review issues with Qin prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.

5. *Independence and Objectivity Certification.* Prior to performing the first Quarterly Claims Review or Dialysis Access Procedures Review, and annually thereafter, the IRO shall provide to Qin a certification that the IRO has (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.C and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in Appendix A to this IA.

D. Ineligible Persons

1. *Definitions.* For purposes of this IA:

a. an "Ineligible Person" shall include an individual or entity who:

i. is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs; or

ii. has been convicted of (a) a criminal offense that is related to the delivery of an item or service under Medicare or any state health care program; (b) a criminal offense relating to neglect or abuse of patients; (c) a felony criminal offense relating to fraud, theft, embezzlement, breach of fiduciary responsibility, or other financial misconduct in connection with the delivery of a health care item or service or with respect to a government funded health care program (other than Medicare or a state health care program); or (d) a felony criminal offense relating to the unlawful manufacture, distribution, prescription or dispensing

of a controlled substance, but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.

- b. “Exclusion Lists” include:
 - i. the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at <http://www.oig.hhs.gov>); and
 - ii. the General Services Administration’s System for Award Management (available through the Internet at <http://www.sam.gov>)

2. *Screening Requirements.* Qin shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements.

- a. Qin shall screen all prospective Covered Persons against the Exclusion Lists prior to engaging their services and, as part of the hiring or contracting process, shall require Covered Persons to disclose whether they are Ineligible Persons.
- b. Qin shall screen all current Covered Persons against the Exclusion Lists within 30 days after the Effective Date and on a monthly basis thereafter.
- c. Qin shall require all Covered Persons to immediately disclose any debarment, exclusion, suspension, or other event that makes that Covered Person an Ineligible Person.

Qin shall maintain documentation demonstrating that Qin: (1) has checked the Exclusion Lists (e.g., print screens from search results) and determined that such individuals or entities are not Ineligible Persons; and (2) has required individuals and entities to disclose if they are an Ineligible Person (e.g., employment applications).

Nothing in this Section affects the Qin’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by excluded persons. Qin understands that items or services furnished by excluded persons are not payable by Federal health care programs and that Qin may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing

or contracting with an excluded person regardless of whether Qin meets the requirements of Section III.D.

3. *Removal Requirement.* If Qin has actual notice that a Covered Person has become an Ineligible Person, Qin shall remove such Covered Person from responsibility for, or involvement with, Qin's business operations related to the Federal health care programs and shall remove such Covered Person from any position for which the Covered Person's compensation or the items or services rendered, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by Federal health care programs or otherwise with Federal funds at least until such time as the Covered Person is reinstated into participation in the Federal health care programs.

4. *Pending Charges and Proposed Exclusions.* If Qin has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person's employment or contract term, Qin shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, patient, or resident, or the accuracy of any claims submitted to any Federal health care program.

E. Notification of Investigation or Legal Proceedings

Within 30 days after discovery, Qin shall notify OIG, in writing, of: 1) any ongoing investigation or legal proceeding known to Qin conducted or brought by a governmental entity or its agents involving an allegation that Qin has committed a crime or has engaged in fraudulent activities and 2) any ongoing investigation or legal proceeding known to Qin conducted or brought by any State licensing authority involving an allegation that Qin has furnished items or services to patients substantially in excess of the needs of such patients or has provided services that fail to meet professionally recognized standards of health care. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency or authority, and the status of such investigation or legal proceeding. Qin shall also provide written notice to OIG within 30 days after the resolution of the matter, and shall provide OIG with a description of the findings and/or results of the proceedings, if any.

F. Repayment of Overpayments

1. *Definition of Overpayments.* For purposes of this IA, an "Overpayment" shall mean the amount of money Qin has received in excess of the amount due and payable under any Federal health care program requirements.

2. *Reporting of Overpayments.* If, at any time, Qin identifies or learns of any Overpayment, Qin shall repay the Overpayment to the appropriate payor (e.g., Medicare contractor) within 60 days after identification of the Overpayment and take steps to correct the problem and prevent the Overpayment from recurring within 90 days after identification (or such additional time as may be agreed to by the payor) to. If not yet quantified within 60 days after identification, Qin shall notify the payor at that time of its efforts to quantify the Overpayment amount and provide a schedule of when such work is expected to be completed. Qin should follow the payor's policies regarding the form of notification and the repayment process for any Overpayment refunds. Any questions regarding the repayment process should be directed to the payor.

G. Reportable Events

1. *Definition of Reportable Event.* For purposes of this IA, a "Reportable Event" means anything that involves:

- a. a substantial Overpayment;
- b. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;
- c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.D.1.a;
- d. the filing of a bankruptcy petition by Qin; or

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. *Reporting of Reportable Events.* If Qin determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Qin shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.

3. *Reportable Events under Section III.G.1.a.* For Reportable Events under Section III.G.1.a, the report to OIG shall be made within 30 days after making the determination that a substantial Overpayment exists, and shall include:

- a. a complete description of all details relevant to the Reportable Event, including, at minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;
- b. the Federal health care programs affected by the Reportable Event;
- c. a description of the steps taken by Qin to identify and quantify the Overpayment; and
- d. a description of Qin's actions taken to correct the Reportable Event and prevent it from recurring.

Within 60 days of identification of the Overpayment, Qin shall send to OIG a copy of the notification and repayment (if quantified) to the payor required by Section III.F.2.

4. *Reportable Events under Section III.G.1.b.* For Reportable Events under Section III.G.1.b, the report to the OIG shall include

- a. a complete description of all details relevant to the Reportable Event, including, at minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;
- b. the Federal health care programs affected by the Reportable Event;
- c. a description of Qin's actions taken to correct the Reportable Event and prevent it from recurring; and

- d. if the Reportable Event has resulted in an Overpayment, a description of the steps taken by Qin to identify and quantify the Overpayment.

5. *Reportable Events under Section III.G.1.c.* For Reportable Events under Section III.G.1.c, the report to OIG shall include:

- a. the identity of the Ineligible Person and the job duties performed by that individual;
- b. the dates of the Ineligible Persons employment or contractual relationship;
- c. a description of the Exclusion Lists screening that Qin completed before and/or during the Ineligible Person's employment or contract and any flaw or breakdown in the Ineligible Persons screening process that led to the hiring or contracting with the Ineligible Person;
- d. a description of how the Reportable Event was discovered; and
- e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

6. *Reportable Events under Section III.G.1.d.* If the Reportable Event involves the filing of a bankruptcy petition, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program authorities implicated.

H. Third Party Billing

If, prior to the Effective Date or at any time during the term of this IA Qin contracts with a third party billing company to submit claims to the Federal health care programs on behalf of Qin, Qin must certify to OIG that he does not have an ownership or control interest (as defined in 42 U.S.C. § 1320a-3(a)(3)) in the third party billing company and is not employed by, and does not act as a consultant to, the third party billing company.

Qin also shall obtain (as applicable) a certification from any third party billing company that the company: (i) has a policy of not employing any person who is excluded, debarred, suspended or otherwise ineligible to participate in Medicare or other Federal health care programs to perform any duties related directly or indirectly to the preparation or submission of claims to Federal health care programs; (ii) screens its prospective and current employees against the HHS/OIG List of Excluded Individuals/Entities and the General Services Administration's System for Award Management; and (iii) provides training in the applicable requirements of the Federal health care programs to those employees involved in the preparation and submission of claims to Federal health care programs.

If applicable, a copy of these certifications shall be included in Qin's Implementation Report and each Annual Report required by Section V below.

IV. SUCCESSOR LIABILITY; CHANGES TO LOCATIONS OR BUSINESS; NEW EMPLOYMENT OR CONTRACTUAL ARRANGEMENT

A. Change or Closure of Location. In the event that, after the Effective Date, Qin changes locations or closes a location related to the furnishing of items or services that may be reimbursed by Federal health care programs, Qin shall notify OIG of this fact as soon as possible, but no later than 30 days after the date of change or closure of the location.

B. Purchase or Establishment of New Location or Business. In the event that, after the Effective Date, Qin purchases or establishes a new location or business related to the furnishing of items or services that may be reimbursed by Federal health care programs, Qin shall notify OIG at least 30 days prior to such purchase or the operation of the new location or business. This notification shall include the address of the new location or business, phone number, fax number, Medicare and state Medicaid program provider identification number and/or supplier number, and the name and address of each Medicare and state Medicaid program contractor to which Qin currently submits claims. Each new location or business and all Covered Persons at each new location or business shall be subject to the applicable requirements of this IA, unless otherwise determined and agreed to in writing by OIG.

C. Sale of Location or Business. In the event that, after the Effective Date, Qin proposes to sell any or all of his locations or businesses that are subject to this IA, Qin shall notify OIG at least 30 days prior to the proposed sale. This notification shall include a description of the location or business to be sold, a brief description of the terms of the sale, and the name and contact information of the prospective purchaser.

This IA shall be binding on the purchaser of such location or business, unless otherwise determined and agreed to in writing by OIG.

D. New Employment or Contractual Arrangement. At least 30 days prior to Qin becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by Federal health care programs, Qin shall notify OIG of his plan to become an employee or contractor and must provide OIG with the name, location, status (employee or contractor) and an explanation of Qin's responsibilities with respect to such potential employer or contractor. In addition, prior to Qin becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by Federal health care programs, Qin shall notify that party of this IA. This notification shall include a copy of the IA and a statement indicating the remaining term of the IA. The IA shall continue to apply to Qin following the start of the new employment or contractual relationship, unless otherwise agreed to in writing by the OIG.

V. **IMPLEMENTATION REPORT, IRO REPORTS AND ANNUAL REPORTS**

A. Implementation Report. Within 90 days after the Effective Date, Qin shall submit a written report to OIG summarizing the status of its implementation of the requirements of this IA (Implementation Report). The Implementation Report shall, at a minimum, include:

1. a copy of the notice Qin posted in his office as required by Section III.A, a description of where the notice is posted, and the date the notice was posted;
2. the following information regarding the one hour of training required by Section III.B to be completed within 60 days of the Effective Date: a copy of the training program registration for each Covered Person who completed the training, the name of the training course, the name of the entity that provided the training, the location, date and length of the training; and a training program brochure or other materials from the training program or training program sponsor that describe the content of the training program.

A copy of all training materials shall be made available to OIG upon request.

3. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate

that the IRO has the qualifications outlined in Appendix A to this IA; (d) a summary and description of any and all current and prior engagements and agreements between Qin and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to Qin;

4. a copy of the documentation demonstrating that Qin has screened all Covered Persons against the Exclusion Lists, as required by section III.D, within 30 days of the Effective Date;

5. a copy of any certifications from Qin and the third party billing company required by Section III.H (if applicable);

6. a list of all of Qin's locations (including locations and mailing addresses), the corresponding name under which each location is doing business, the corresponding phone numbers and fax numbers, each location's Medicare and state Medicaid program provider identification number(s), and/or supplier number(s), and the name and address of each Medicare and state Medicaid program contractor to which Qin currently submits claims; and

7. a certification by Qin that: (a) he has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his knowledge, except as otherwise described in the Implementation Report, Qin is in compliance with all of the requirements of this IA; and (c) he has reviewed the Implementation Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful.

B. IRO Reports. Within 60 days following the end of each three-month period during the term of this IA, Qin shall provide to OIG a copy of: (1) the Quarterly Claims Review prepared by the IRO for each Quarterly Claims Review and (2) a response and corrective action plan related to any recommendations made by the IRO in the Quarterly Claims Review Report. Each Quarterly Claims Review Report shall include the information specified in Appendix B to this IA.

C. Annual Reports. Qin shall submit to OIG Annual Reports with respect to the status of, and findings regarding, Qin's compliance activities for each of the three Reporting Periods (Annual Report).

Each Annual Report shall, at a minimum, include:

1. a description of any changes to the notice required by Section III.A, and the reason for such changes, along with a copy of the revised notice;
2. the following information regarding the additional two hours of training required by Section III.B during the first reporting period (and any additional hours of training required for the second and third reporting periods): a copy of the training program registration for each Covered Person who completed the training, the name of the training course, the name of the entity that provided the training, the location, date and length of the training; and a training program brochure or other materials from the training program or training program sponsor that describe the content of the training program;

A copy of all training materials shall be made available to OIG upon request.

3. a certification from each IRO regarding its professional independence and objectivity with respect to Qin;
4. a copy of the documentation demonstrating that Qin screened all prospective and current Covered Persons against the Exclusion Lists, as required by section III.D;
5. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.E. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;
6. a summary of Reportable Events (as defined in Section III.G) identified during the Reporting Period and the status of any corrective action relating to all such Reportable Events;
7. a report of the aggregate Overpayments that have been returned to the Federal health care programs during the Reporting Period. Overpayment amounts shall be broken down into the following categories: Medicare, Medicaid, and other Federal health care programs;
8. a copy of any certifications from Qin and the third party billing company required by Section III.H (if applicable);

9. a description of all changes to the most recently provided list of Qin's locations (including addresses) as required by Section V.A.6;

10. a certification signed by Qin that: (a) he has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his knowledge, except as otherwise described in the Annual Report, Qin is in compliance with all of the requirements of this IA; and (c) he has reviewed the Annual Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful; and

11. a copy of: (1) the Dialysis Access Procedures Review prepared by the IRO for Dialysis Access Procedures Review and (2) a response and corrective action plan related to any recommendations made by the IRO in the Dialysis Access Procedures Review, including a response and explanation related to any instances in which the IRO determined that a particular Dialysis Access Procedure (as defined in Appendix B) was not medically necessary as indicated on the spreadsheet prepared pursuant to Section G.3.c. of Appendix B for each Dialysis Access Procedures Review. Each Dialysis Access Procedures Review shall include the information specified in Appendix B to this IA.

The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

D. Designation of Information. Qin shall clearly identify any portions of its submissions that he believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Qin shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI. NOTIFICATIONS AND SUBMISSION OF REPORTS

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this IA shall be submitted to the following entities:

OIG:
Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General

Office of Inspector General
U.S. Department of Health and Human Services
Cohen Building, Room 5527
330 Independence Avenue, SW
Washington, DC 20201
Telephone: (202) 619-2078
Facsimile: (202) 205-0604

Qin:
Feng Qin, M.D.
Qin Medical PC
123 Lafayette St, 5th Floor
New York, NY 10013
Telephone: (212) 966-0033

Unless otherwise specified, all notifications and reports required by this IA shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, Qin may be required to provide OIG with an electronic copy of each notification or report required by this IA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

VII. OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may examine or request copies of Qin's books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Qin's locations for the purpose of verifying and evaluating: (a) Qin's compliance with the terms of this IA; and (b) Qin's compliance with the requirements of the Federal health care programs. The documentation described above shall be made available by Qin to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview Qin and any of Qin's employees, contractors, or agents who consent to be interviewed at the individual's place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Qin shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG's request. Qin's employees may elect to be interviewed with or without a representative of Qin present.

VIII. DOCUMENT AND RECORD RETENTION

Qin shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this IA for four years (or longer if otherwise required by law) from the Effective Date.

IX. DISCLOSURES

Consistent with HHS's FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Qin prior to any release by OIG of information submitted by Qin pursuant to its obligations under this IA and identified upon submission by Qin as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Qin shall have the rights set forth at 45 C.F.R. § 5.65(d).

X. BREACH AND DEFAULT PROVISIONS

Qin is expected to fully and timely comply with all of his IA obligations.

A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, Qin and OIG hereby agree that failure to comply with certain obligations set forth in this IA (unless a timely written request for an extension has been submitted and approved in accordance with Section B below) may lead to the imposition of the following monetary penalties (hereinafter referred to as "Stipulated Penalties") in accordance with the following provisions.

1. A Stipulated Penalty of \$1,000 (which shall begin to accrue on the day after the date the obligation became due) for each day Qin fails to:

- a. establish and/or post a notice in accordance with the requirements of Section III.A;
- b. complete the training required for Qin and Covered Persons and maintain training certifications, in accordance with the requirements of Section III.B;
- c. engage and use an IRO in accordance with the requirements of Section III.C, Appendix A, and Appendix B;

- d. screen Covered Persons in accordance with the requirements of Section III.D; or require Covered Persons to disclose if they are debarred, excluded, suspended or are otherwise considered an Ineligible Person in accordance with the requirements of Section III.D; and maintain documentation of screening and disclosure requirements in accordance with the requirements of Section III.D;
- e. notify OIG of a government investigation or legal proceeding, in accordance with the requirements of Section III.E;
- f. repay any Overpayments in accordance with Section III.F;
- g. report a Reportable Event in accordance with Section III.G.;
- h. provide to OIG the certifications required by Section III.H relating to any third party biller engaged by Qin during the term of the IA; or
- i. provide the notices required by Section IV.

2. A Stipulated Penalty of \$1,500 (which shall begin to accrue on the day after the date the obligation became due) for each day Qin fails to submit the Implementation Report, Quarterly Claims Review Report, Dialysis Access Procedures Review Report, or the Annual Reports to OIG in accordance with the requirements of Section V by the deadlines for submission.

3. A Stipulated Penalty of \$1,000 for each day Qin fails to grant access as required in Section VII. (This Stipulated Penalty shall begin to accrue on the date Qin fails to grant access.)

4. A Stipulated Penalty of \$50,000 for each false certification submitted by or on behalf of Qin as part of its Implementation Report, Annual Reports, additional documentation to a report (as requested by OIG), or as otherwise required by this IA.

5. A Stipulated Penalty of \$1,000 for each day Qin fails to comply fully and adequately with any obligation of this IA. OIG shall provide notice to Qin stating the specific grounds for its determination that Qin has failed to comply fully and adequately with the IA obligation(s) at issue and steps the Qin shall take to comply with the IA.

(This Stipulated Penalty shall begin to accrue 10 days after the date Qin receives this notice from OIG of the failure to comply.) A Stipulated Penalty as described in this Subsection shall not be demanded for any violation for which OIG has sought a Stipulated Penalty under Subsections 1-4 of this Section.

B. Timely Written Requests for Extensions. Qin may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or Report required by this IA. Notwithstanding any other provision in this Section, if OIG grants the timely written request with respect to an act, notification, or Report, Stipulated Penalties for failure to perform the act or file the notification or Report shall not begin to accrue until one day after Qin fails to meet the revised deadline set by OIG. Notwithstanding any other provision in this Section, if OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or Report shall not begin to accrue until three business days after Qin receives OIG's written denial of such request or the original due date, whichever is later. A "timely written request" is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. Payment of Stipulated Penalties.

1. *Demand Letter.* Upon a finding that Qin has failed to comply with any of the obligations described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall notify Qin of: (a) Qin's failure to comply; and (b) OIG's intent to exercise its contractual right to demand payment of the Stipulated Penalties. (This notification shall be referred to as the "Demand Letter.")

2. *Response to Demand Letter.* Within 10 days of the receipt of the Demand Letter, Qin shall either: (a) cure the breach to OIG's satisfaction and pay the applicable Stipulated Penalties; or (b) send in writing to OIG a request for a hearing before an HHS administrative law judge (ALJ) to dispute OIG's determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E. In the event Qin elects to request an ALJ hearing, the Stipulated Penalties shall continue to accrue until Qin cures, to OIG's satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one of these two manners within the allowed time period shall be considered a material breach of this IA and shall be grounds for exclusion under Section X.D.

3. *Form of Payment.* Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

4. *Independence from Material Breach Determination.* Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG's decision that Qin has materially breached this IA, which decision shall be made at OIG's discretion and shall be governed by the provisions in Section X.D, below.

D. Exclusion for Material Breach of this IA.

1. *Definition of Material Breach.* A material breach of this IA means:
 - a. a failure by Qin to report a Reportable Event, take corrective action, or make the appropriate refunds, as required in Section III.G;
 - b. repeated violations or a flagrant violation of any of the obligations under this IA, including, but not limited to, the obligations addressed in Section X.A;
 - c. a failure to respond to a Demand Letter concerning the payment of Stipulated Penalties in accordance with Section X.C; or
 - d. a failure to engage and use an IRO in accordance with Section III.C, Appendix A, and Appendix B.

2. *Notice of Material Breach and Intent to Exclude.* The parties agree that a material breach of this IA by Qin constitutes an independent basis for Qin's exclusion from participation in the Federal health care programs. The length of the exclusion shall be in the OIG's discretion, but not more than three years per material breach. Upon a determination by OIG that Qin has materially breached this IA and that exclusion is the appropriate remedy, OIG shall notify Qin of: (a) Qin's material breach; and (b) OIG's intent to exercise its contractual right to impose exclusion. (This notification shall be referred to as the "Notice of Material Breach and Intent to Exclude.")

3. *Opportunity to Cure.* Qin shall have 30 days from the date of receipt of the Notice of Material Breach and Intent to Exclude to demonstrate that:
 - a. the alleged material breach has been cured; or

- b. the alleged material breach cannot be cured within the 30-day period, but that: (i) Qin has begun to take action to cure the material breach; (ii) Qin is pursuing such action with due diligence; and (iii) Qin has provided to OIG a reasonable timetable for curing the material breach.

4. *Exclusion Letter.* If, at the conclusion of the 30 day period, Qin fails to satisfy the requirements of Section X.D.3, OIG may exclude Qin from participation in the Federal health care programs. OIG shall notify Qin in writing of its determination to exclude Qin. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of Qin’s receipt of the Exclusion Letter. The exclusion shall have national effect. Reinstatement to program participation is not automatic. At the end of the period of exclusion, Qin may apply for reinstatement, by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-3004.

E. Dispute Resolution.

1. *Review Rights.* Upon OIG’s delivery to Qin of its Demand Letter or of its Exclusion Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this IA, Qin shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or exclusion sought pursuant to this IA. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the HHS Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing involving Stipulated Penalties shall be made within 10 days after the receipt of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after receipt of the Exclusion Letter. The procedures relating to the filing of a request for a hearing can be found at <http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html>.

2. *Stipulated Penalties Review.* Notwithstanding any provision of Title 42 of the United States Code or Chapter 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this IA shall be: (a) whether Qin was in full and timely compliance with the obligations of this IA for which OIG demands payment; and (b) the period of noncompliance. Qin shall have the burden of proving its full and timely compliance and the steps taken to cure the noncompliance, if any. OIG shall not have the right to appeal to the DAB an adverse ALJ decision related to

Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of this IA and orders Qin to pay Stipulated Penalties, such Stipulated Penalties shall become due and payable 20 days after the ALJ issues such a decision unless Qin requests review of the ALJ decision by the DAB. If the ALJ decision is properly appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated Penalties shall become due and payable 20 days after the DAB issues its decision.

3. *Exclusion Review.* Notwithstanding any provision of Title 42 of the United States Code or Chapter 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this IA shall be whether Qin was in material breach of this IA and, if so:

- a. Qin cured such breach within 30 days of its receipt of the Notice of Material Breach; or
- b. the alleged material breach could not have been cured within the 30-day period, but that, during the 30-day period following Qin's receipt of the Notice of Material Breach: (i) Qin had begun to take action to cure the material breach; (ii) Qin pursued such action with due diligence; and (iii) Qin provided to OIG a reasonable timetable for curing the material breach.

For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision favorable to OIG, or, if the ALJ rules for Qin, only after a DAB decision in favor of OIG. Qin's election of its contractual right to appeal to the DAB shall not abrogate OIG's authority to exclude Qin upon the issuance of an ALJ's decision in favor of OIG. If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that Qin may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Qin shall waive his right to any notice of such an exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Qin, Qin shall be reinstated effective the date of the original exclusion.

4. *Finality of Decision.* The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. Consequently, the parties to this IA agree that the DAB's decision (or the ALJ's decision if not appealed) shall be considered final for all purposes under this IA.

XI. EFFECTIVE AND BINDING AGREEMENT

Qin and OIG agree as follows:

A. This IA shall become final and binding on the date the final signature is obtained on the IA.

B. This IA constitutes the complete agreement between the parties and may not be amended except by prior written consent of the parties to this IA.

C. OIG may agree to a suspension of Qin's obligations under this IA based on a certification by Qin that he is no longer providing health care items or services that will be billed to any Federal health care programs and he does not have any ownership or control interest in any entity that bills any Federal health care program. If Qin is relieved of his IA obligations, Qin shall be required to notify OIG in writing at least 30 days in advance if Qin plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, the OIG shall evaluate whether the IA will be reactivated or modified.

D. All requirements and remedies set forth in this IA are in addition to, and do not affect (1) Qin's responsibility to follow all applicable Federal health care program requirements or (2) the government's right to impose appropriate remedies for failure to follow applicable program requirements.

E. The undersigned Qin signatory represents and warrants that he is authorized to execute this IA. The undersigned OIG signatories represent that they are signing this IA in their official capacity and that they are authorized to execute this IA.

F. This IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same IA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this IA.

ON BEHALF OF QIN

/Feng Qin, M.D./

April 29, 2015

Feng Qin, M.D.

DATE

/Mark L. Furman/

4/29/15

Counsel for Qin
Mark L. Furman
Hoffman Polland & Furman PLLC

DATE

**ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES**

/Robert K. DeConti/

4/27/15

Robert K. DeConti
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
U. S. Department of Health and Human Services

DATE

/Tamara T. Forys/

4/29/2015

Tamara T. Forys
Senior Counsel
Office of Counsel to the Inspector General
Office of Inspector General
U. S. Department of Health and Human Services

DATE

APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.C of the IA.

A. IRO Engagement

1. Qin shall engage one or more IROs that possess the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph D. Within 30 days after OIG receives the information identified in Section V.A.3 of the IA or any additional information submitted by Qin in response to a request by OIG, whichever is later, OIG will notify Qin if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Qin may continue to engage the IRO.

2. If Qin engages a new IRO during the term of the IA, this IRO shall also meet the requirements of this Appendix. If a new IRO is engaged, Qin shall submit the information identified in Section V.A.3 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information, or any additional information submitted by Qin at the request of OIG, whichever is later, OIG will notify Qin if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Qin may continue to engage the IRO.

B. IRO Qualifications

The IRO for the Quarterly Claims Review shall:

1. assign individuals to conduct the Quarterly Claims Review who have expertise in the billing, coding, claims submission, and other Federal health care program requirements relating to claims for items and services submitted by Qin;

2. assign individuals to design and select the Quarterly Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques;

3. assign individuals to conduct the coding review portions of the Quarterly Claims Review who have a nationally recognized coding certification and who

have maintained this certification (e.g., completed applicable continuing education requirements); and

4. have sufficient staff and resources to conduct the Quarterly Claims Reviews required by the IA on a timely basis.

The IRO for the Dialysis Access Procedures Review shall:

1. assign individuals to conduct the Dialysis Access Procedures Review who are medical professionals who have clinical expertise in vascular and endovascular procedures and specifically, medical necessity and appropriateness of dialysis access procedures and tests, and in the billing, coding, claims submission, and other Federal health care program reimbursement requirements for dialysis access procedures and tests;

2. assign individuals to design and select the Dialysis Access Procedures Review sample who are knowledgeable about the appropriate statistical sampling techniques; and

3. have sufficient staff and resources to conduct the Dialysis Access Procedures Reviews required by the IA on a timely basis.

C. IRO Responsibilities

The IRO shall:

1. perform each Quarterly Claims Review and Dialysis Access Procedures Review in accordance with the specific requirements of the IA;

2. follow all applicable Federal health care program Medicare rules and reimbursement guidelines in making assessments in the Quarterly Claims Review and Dialysis Access Procedures Review;

3. if in doubt of the application of a particular Federal health care program policy or regulation, request clarification from the appropriate authority (e.g., fiscal intermediary or carrier);

4. respond to all OIG inquiries in a prompt, objective, and factual manner; and

5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the IA.

D. IRO Independence and Objectivity

The IRO must perform the Quarterly Claims Review and the Dialysis Access Procedures Review (as applicable) in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the United States Government Accountability Office.

E. IRO Removal/Termination

1. *Qin and IRO.* If Qin terminates its IRO or the IRO withdraws from the engagement during the term of the IA, Qin must submit a notice explaining its reasons for termination or the reason for withdrawal to OIG no later than 30 days after termination or withdrawal. Qin must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

2. *OIG Removal of IRO.* In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph D, or has failed to carry out its responsibilities as described in Paragraph C, OIG may, at its sole discretion, require Qin to engage a new IRO in accordance with Paragraph A of this Appendix. Qin must engage a new IRO within 60 days of termination of the IRO.

Prior to requiring Qin to engage a new IRO, OIG shall notify Qin of its intent to do so and provide a written explanation of why OIG believes such a step is necessary. To resolve any concerns raised by OIG, Qin may present additional information regarding the IRO's qualifications, independence or performance of its responsibilities. OIG will attempt in good faith to resolve any differences regarding the IRO with Qin prior to requiring Qin to terminate the IRO. However, the final determination as to whether or not to require Qin to engage a new IRO shall be made at the sole discretion of OIG.

APPENDIX B

CLAIMS REVIEW AND DIALYSIS ACCESS PROCEDURES REVIEW

The IRO(s) shall perform two reviews under this IA: (1) a review of Qin's coding, billing, and claims submission to the Federal health care programs, and the reimbursement received, for each three-month period during the term of this IA (Quarterly Claims Review) and (2) a review of the medical necessity and appropriateness of AV dialysis access interventions and dialysis access dysfunction diagnostic tests performed or ordered by Qin, for each Reporting Period during the term of this IA (Dialysis Access Procedures Review). The IRO shall prepare a report for each Quarterly Claims Review (Quarterly Claims Review Report) and each Dialysis Access Procedures Review (Dialysis Access Procedures Review Report) performed. The first three-month period for the Quarterly Claims Review Report shall begin 30 days following the Effective Date of this IA.

A. *Definitions.* For the purposes of this Appendix B, the following definitions shall be used:

1. Overpayment: The amount of money Qin has received in excess of the amount due and payable under any Federal health care program requirements, as determined by the IRO in connection with the claims reviews performed under this Appendix B, and which shall include any extrapolated Overpayments determined in accordance with Section B.2 of this Appendix B.
2. Paid Claim: A claim submitted by Qin and for which Qin has received reimbursement from the Medicare, Medicaid, or any Federal health care program.
3. Quarterly Claims Review Population: The Population for the Quarterly Claims Review shall be defined as all Paid Claims during the three-month period covered by the Quarterly Claims Review.
4. Dialysis Access Procedures: For purposes of this Appendix B, Dialysis Access Procedures includes Arteriovenous (AV) dialysis access (AV fistula, AV dialysis graft) interventions and dialysis access dysfunction diagnostic tests, including fistulagrams, fistuloplasties, and angioplasties performed or ordered by Qin.

5. Dialysis Access Procedures Review Population: The Population for each Dialysis Access Procedures Review shall be defined as all Dialysis Access Procedures performed by Qin for which Qin has received reimbursement from Medicare, Medicaid, or other Federal health care programs (Dialysis Access Procedures Paid Claims) during the Reporting Period covered by the Dialysis Access Procedures Review.
6. Error Rate: The Error Rate shall be the percentage of net Overpayments identified in the sample. The net Overpayments shall be calculated by subtracting all underpayments identified in the sample from all gross Overpayments identified in the sample.

The Error Rate is calculated by dividing the net Overpayment identified in the sample by the total dollar amount associated with the Paid Claims in the sample.

B. Quarterly Claims Review.

1. *Quarterly Claims Review Sample.* Within 15 days following the end of each three-month period during the term of this IA, the IRO shall randomly select a sample of 40 Paid Claims submitted by or on behalf of Qin during the preceding three-month period (Quarterly Claims Sample). The sample must be selected through the use of OIG's Office of Audit Services' Statistical Sampling Software, also known as RAT-STATS, which is currently available at <https://oig.hhs.gov/compliance/rat-stats/index.asp>. Qin shall provide the IRO with a list of all Qin's Paid Claims for the three-month period covered by the Quarterly Claims Sample. The IRO should number each Paid Claim in the Population sequentially prior to generating the random numbers used to select the Quarterly Claims Sample. The IRO should generate 40 random numbers using RAT-STATS and then use the random numbers to identify the 40 Paid Claims in the Population that will be subject to review by the IRO. The randomly selected 40 Paid Claims will be reviewed by the IRO based on the supporting documentation available at Qin's office or under Qin's control and applicable billing and coding regulations and guidance to determine whether each claim was correctly coded, submitted, and reimbursed. The IRO shall prepare a written report of its findings from the Quarterly Claims Sample, as described in Section D below (Quarterly Claims Review Report). The Quarterly Claims Review Report shall be submitted to the OIG within 60 days following the end of the three-month period covered by each Quarterly Claims Review.

2. *Additional Steps if Error Rate is 5% or Greater.* If the Error Rate (as defined above) for any Quarterly Claims Review performed is 5% or greater, the IRO will estimate the actual Overpayment in the Population for that three-month period by identifying the point estimate. To identify the point estimate, the IRO shall extrapolate the Error Rate as determined in the Quarterly Claims Sample to the Population for the applicable Quarterly Claims Review. Qin shall be required to repay the point estimate of the extrapolated Overpayment in accordance with Section E, below. OIG, in its sole discretion, may refer the findings of the Quarterly Claims Sample (and any related workpapers) to the appropriate Federal health care program payor for appropriate follow-up by that payor. The Quarterly Claims Review Report prepared by the IRO shall indicate the extrapolated Overpayment amount and the methodology used by the IRO to determine the extrapolated Overpayment amount.

C. Dialysis Access Procedures Review.

1. *Dialysis Access Procedures Sample.* The IRO shall randomly select a sample of 40 Dialysis Access Procedure Paid Claims (Dialysis Access Procedures Sample). The sample must be selected through the use of OIG's Office of Audit Services' Statistical Sampling Software, also known as RAT-STATS, which is currently available at <https://oig.hhs.gov/compliance/rat-stats/index.asp>. Qin shall provide the IRO with a list of all Qin's Dialysis Access Procedure Paid Claims for the Reporting Period covered by the Dialysis Access Procedures Sample, except those Dialysis Access Procedures performed at St. John's Episcopal Hospital, Far Rockaway, New York shall not be included in the Dialysis Access Procedures Sample. The IRO should number each Dialysis Access Procedure Paid Claim in the Population sequentially prior to generating the random numbers used to select the Dialysis Access Procedures Sample. The IRO should generate 40 random numbers using RAT-STATS and then use the random numbers to identify the 40 Dialysis Access Procedure Paid Claims in the Population that will be subject to review by the IRO. The randomly selected 40 Dialysis Access Procedure Paid Claims will be reviewed by the IRO based on the supporting documentation available at Qin's office or under Qin's control and applicable regulations and guidance, including but not limited to the established practice guidelines described by the Local Coverage Determination for Dialysis Access Maintenance and generally accepted standards of medical practice as described by the American Board of Surgery or Society for Clinical Vascular Surgery, to determine whether each procedure was medically necessary or appropriate. If a Dialysis Access Procedure is found not to be medically necessary or appropriate the Dialysis Access Procedure Paid Claim should be deemed an Overpayment. The IRO shall prepare a written report of its findings from the Dialysis Access Procedures Sample, as described in Section D below (Dialysis Access Procedures Review Report) that will be submitted with Qin's Annual Report.

2. *Additional Steps if Error Rate is 5% or Greater.* If the Error Rate (as defined above) for any Dialysis Access Procedures Review performed is 5% or greater, the IRO will estimate the actual Overpayment in the Population for that Reporting Period by identifying the point estimate. To identify the point estimate, the IRO shall extrapolate the Error Rate as determined in the Dialysis Access Procedures Sample to the Dialysis Access Procedures Population for the applicable Dialysis Access Procedures Review. Qin shall be required to repay the point estimate of the extrapolated Overpayment in accordance with Section E, below. OIG, in its sole discretion, may refer the findings of the Dialysis Access Procedures Review (and any related workpapers) to the appropriate Federal health care program payor for appropriate follow-up by that payor. The Dialysis Access Procedures Review Report prepared by the IRO shall indicate the extrapolated Overpayment amount and the methodology used by the IRO to determine the extrapolated Overpayment amount.

D. Claims Review and Dialysis Access Procedures Review Reports. The IRO shall prepare a Claims Review Report for each Quarterly Claims Review performed (Quarterly Claims Review Report) and a Dialysis Access Procedures Review Report for each Dialysis Access Procedures Review performed.

1. Quarterly Claims Review Report. The following information shall be included in each Quarterly Claims Review Report:

a. *Claims Review Methodology.*

i. Claims Review Population. A description of the Population subject to the Quarterly Claims Review.

ii. Source of Data. A description of the specific documentation relied upon by the IRO when performing the Quarterly Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare contractor manual or bulletins (including issue and date), other policies, regulations, or directives).

iii. Review Protocol. A narrative description of how the

Quarterly Claims Review was conducted and what was evaluated.

iv. Supplemental Materials. The IRO shall request all documentation and materials required for its review of the Paid Claims selected as part of each Quarterly Claims Sample and Qin shall furnish such documentation and materials to the IRO, prior to the IRO initiating its review of the Quarterly Claims Sample. If the IRO accepts any supplemental documentation or materials from Qin after the IRO has completed its initial review of the Quarterly Claims Sample (Supplemental Materials), the IRO shall identify in the Quarterly Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Quarterly Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO's reasons for accepting the Supplemental Materials.

b. *Statistical Sampling Documentation*. A copy of the printout of the random numbers generated by the "Random Numbers" function of RAT-STATS used by the IRO to select the Quarterly Claims Sample.

c. *Claims Review Findings*.

i. Narrative Results.

(1) For the first Quarterly Claims Review Report only, a description of Qin's billing and coding system(s), including the identification, by position description, of the personnel involved in coding and billing. Subsequent Quarterly Claims Review Reports should describe any significant changes to Qin's billing and coding system or, if no significant changes were made, state that the billing and coding systems remain the same as described in the prior Quarterly Claims Review Report.

(2) A narrative explanation of the results of the Quarterly Claims Sample, including reasons for errors,

patterns noted, etc.

ii. Quantitative Results.

(1) Total number and percentage of instances in which the IRO determined that the Paid Claims submitted by Qin (Claim Submitted) differed from what should have been the correct claim (Correct Claim), regardless of the effect on the payment.

(2) Total number and percentage of instances in which the Claim Submitted differed from the Correct Claim and in which such difference resulted in an Overpayment to Qin.

(3) Total dollar amount of all Overpayments in the sample.

(4) Total dollar amount of Paid Claims included in the sample and the net Overpayment associated with the sample.

(5) Error Rate in the sample.

(6) A spreadsheet of the Quarterly Claims Sample results that includes the following information for each Paid Claim: Federal health care program billed, beneficiary health insurance claim number, date of service, procedure code submitted, procedure code reimbursed, allowed amount reimbursed by payor, correct procedure code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount.

d. *Recommendations.* The IRO's report shall include any recommendations for improvements to Qin's billing and coding system based on the findings of the Quarterly Claims Review.

e. *Credentials.* The names and credentials of the individuals who: (1) designed the review methodology utilized for the Quarterly Claims Review and

(2) performed the Quarterly Claims Review.

2. Dialysis Access Procedures Review Report. The following information shall be included in each Dialysis Access Procedures Review Report:

a. *Dialysis Access Procedures Review Methodology*.

i. Dialysis Access Procedures Review Population. A description of the Population subject to the Dialysis Access Procedures Review.

ii. Source of Data. A description of the specific documentation relied upon by the IRO when performing the Dialysis Access Procedures Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare contractor manual or bulletins (including issue and date), other policies, regulations, or directives).

iii. Review Protocol. A narrative description of how the Dialysis Access Procedures Review was conducted and what was evaluated.

iv. Supplemental Materials. The IRO shall request all documentation and materials required for its review of the Dialysis Access Procedures selected as part of each Dialysis Access Procedures Sample and Qin shall furnish such documentation and materials to the IRO, prior to the IRO initiating its review of the Dialysis Access Procedures Sample. If the IRO accepts any supplemental documentation or materials from Qin after the IRO has completed its initial review of the Dialysis Access Procedures Sample (Supplemental Materials), the IRO shall identify in the Dialysis Access Procedures Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Dialysis Access Procedures Review Report

describing the process by which the Supplemental Materials were accepted and the IRO's reasons for accepting the Supplemental Materials.

b. *Statistical Sampling Documentation.* A copy of the printout of the random numbers generated by the "Random Numbers" function of RAT-STATS used by the IRO to select the Dialysis Access Procedures Sample.

c. *Dialysis Access Procedures Review Findings.*

i. Narrative Results

1. A narrative explanation of the IRO's findings and supporting rationale (including reasons for errors, patterns noted, etc.) regarding the Dialysis Access Procedures Review, including reasons for the errors, patterns noted, etc.

ii. Quantitative Results

1. Total number and percentage of instances in which the IRO determined that the Dialysis Access Procedures were not medically necessary or appropriate and therefore the corresponding claim differed from what should have been the correct claim (Correct Claim).

2. Total number and percentage of instances in which the claim submitted for Dialysis Access Procedures differed from the Correct Claim and in which such difference resulted in an Overpayment to Qin.

3. Total dollar amount of all Overpayments in the sample.

4. Error Rate in the sample.

5. A spreadsheet of the Dialysis Access Procedures Review results that includes the following

information for each Dialysis Access Procedure appraised: type of Dialysis Access Procedure performed, whether the Dialysis Access Procedure was medically necessary and appropriate, beneficiary name, beneficiary health insurance claim number, date of service, procedure code submitted, Federal health care program billed, amount reimbursed, and allowed amount reimbursed by payor, correct procedure code (as determined by the IRO), correct allowed amount (as determined by the IRO), dollar difference between allowed amount reimbursed by payor and the correct allowed amount.

d. *Credentials.* The names and credential of the individuals who: (1) designed the review methodology utilized for the Dialysis Access Procedures Review and (2) performed the Dialysis Access Procedures Review.

E. Other Requirements. The following requirements apply to any Quarterly Claims Review and Dialysis Access Procedures Review performed pursuant to this Appendix B.

1. Paid Claims without Supporting Documentation. Any Paid Claim (including any Dialysis Access Procedures Paid Claim) for which Qin cannot produce documentation sufficient to support the Paid Claim shall be considered an error and the total reimbursement received by Qin for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted.

2. Use of First Samples Drawn. For the purposes of all samples discussed in this Appendix, the Paid Claims and Dialysis Access Procedures Paid Claims selected in each first sample shall be used (*i.e.*, it is not permissible to generate more than one list of random samples and then select one for use with the sample).

F. Repayment of Identified Overpayments. Qin shall repay within 60 days any Overpayment(s) identified in each Quarterly Claims Sample and Dialysis Access Procedures Sample (including any extrapolated amounts identified in accordance with Section A.3 of this Appendix), regardless of the Error Rate, to the appropriate payor and in accordance with payor refund policies. Qin shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor.